title: Efficacy of two dose regimes of intravenous immunoglobulin in Rh hemolytic disease of newborn--a randomized controlled trial.
abstract: OBJECTIVE
  To compare the effect of two dose regimes of IVIg (0.5 g/kg vs. 1g/kg given soon after birth) on duration of phototherapy in Rh-isoimmunized neonates 32 week and above gestation.
  
  
  METHODS
  Randomized controlled trial.
  
  
  METHODS
  Tertiary care hospital.
  
  
  METHODS
  Rh positive blood group neonates of gestation 32 weeks and above born to Rh negative mothers having positive Direct Coombs test and without any major malformation.
  
  
  METHODS
  Intravenous immunoglobulin (IVIg) infusion over 2 h either 0.5 g/kg (low dose group, n=19) or 1.0 g/kg (high dose group, n=19).
  
  
  METHODS
  Duration of phototherapy.
  
  
  RESULTS
  The mean duration of phototherapy was 77.3+/-57.2 h in low dose group versus 55.4+/-49 h in high dose group (mean difference=21.9; 95% CI-13.1 to 56.9). There was no difference in need for exchange transfusion (21% in both the groups) and requirement of packed red blood cells transfusion (12 transfusions in both groups). The duration of hospital stay was similar [8.4+/-6.9 and 13.6+/-14.8 days, respectively (mean difference=-5.1; 95% CI-12.8 to 2.5)]. No adverse effects of IVIg administration were noted.
  
  
  CONCLUSIONS
  Two regimens of IVIg (0.5 g/Kg or 1 g/Kg) had comparable effect on duration of phototherapy, duration of hospital stay and exchange transfusion requirement, in Rh isoimmunized neonates of gestation 32 weeks and above.
authors: Division of Neonatology, Department of Pediatrics, WHO Collaborating Centre for Training and Research in Newborn Care, All India Institute of Medical Sciences, New Delhi 110 029, India.
authors: G
authors: G
authors: Girish
authors: D
authors: D
authors: Chawla
authors: R
authors: R
authors: Agarwal
authors: V K
authors: VK
authors: Paul
authors: A K
authors: AK
authors: Deorari
mesh_terms: D004899:Erythroblastosis, Fetal / Q000188:drug therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007231:Infant, Newborn; D012204:Rh-Hr Blood-Group System
chemical_list: D016756:Immunoglobulins, Intravenous; D012204:Rh-Hr Blood-Group System